Btcs Inc. Shares Rise 2.7% as Company Announces Phase II/III Cancer Trial with Summit Therapeutics
Btcs Inc. rises 2.7% as it partners with Summit Therapeutics for a new biliary tract cancer trial, while market cap hits $61 M and shares trade around $1.10.
2 minutes to read